Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Capecitabine
Xeloda
Routinely available
Local application
29/03/2023
Indication
Peri-operative treatment of operable gastric and type 3 oesophagogastric junctional adenocarcinomas.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
epirubicin (Pharmorubicin), cisplatin (Platinex) and capecitabine (Xeloda)
Comments
-